SUMMAxY Drug prescribing patterns for the management of inpatients and outpatients with rheumatoid arthritis (RA) were investigated. The population of patients resembled published epidemiological descriptions of RA patients with respect to age and sex distribution. Multiple drug therapy was common in the treatment of both hospitalised and clinic patients. 90% of all patients with RA received non-steroidal anti-inflammatory drug (NSAID) therapy, indomethacin and naproxen being the two most frequently prescribed NSAIDs for both in-and outpatients. The vast majority of inpatients (85%) and outpatients (79%) received slow-acting antirheumatic drug (SAARD) treatment. 13% of hospitalised patients received H2-antagonist drugs in addition to their NSAIDs. A high proportion of inpatients (46%) received oral corticosteroids in the management of their rheumatoid arthritis, while only 15% of clinic patients were prescribed corticosteroids.
classical rheumatoid arthritis according to the American Rheumatism Association (ARA) criteria9 were admitted to the survey.
Drug prescribing data Individual medication registration sheets are stored in the pharmacy department by ward specialty (i.e., rheumatology) and per time period (quarter). Drug prescribing details were compiled directly from these sheets as follows: antiarthritic drug or drug combinations, prescribed daily dosages, and all coprescribed drugs for each patient.
OUTPATIENT DATA COLLECTION Patient data A one-month prospective survey of rheumatoid arthritis patients treated in the Sint Radboud Hospital Outpatient Clinic was conducted. Only patients with definite or classical rheumatoid arthritis9 were admitted to the survey. The data represent a cross-sectional definition of a clinic population. The following patient information was compiled: age, sex, and the current patient disability status based on the ARA functional classl as assessed by the physician during the consultation.
Drug prescribing data At the time of the consultation the drug prescribing data were recorded as follows: antiarthritic drug or drug combinations, dosage form, prescribed daily dosage, frequency, and all coprescribed drugs. Patterns of drug prescribing of individual drugs and particular drug combinations were then determined.
Results

PATIENT CHARACTERISTICS
Inpatients
A total of 166 patients were admitted to the rheumatology ward during the 12-month survey period. Of these, 108 patients (65%) had a diagnosis of probable, definite, or classical rheumatoid arthritis and were included in the study. The age and sex distribution of the RA patients admitted to the rheumatology ward is shown in Fig. la The disability distribution of outpatients by age and sex according to the ARA functional capacity rating is shown in Fig. 2 . It can be seen that the majority of patients fall into disability rating 2, and no patient under the age of 40 had a disability rating of 3. No patient had a disability rating of 4. 
SAARD prescribing data
The prescribing frequency of the SAARDs for inpatients, which from Fig. 3a can be seen to be used mostly in multiple drug therapy, is summarised in SAARD Usage (I) .RAInpatients n-92 (E) Fig. 5a . Azathioprine had the highest usage (38% of SAARD-treated patients), followed by aurothioglucose (34%), and D-penicillamine (26%).
The outpatient prescribing frequency of indi-SAARD Usage(%) RA Outpatients n= 120
Fig. 5 Prescribing pattern for slow-acting antiarthritic drug (SAARD) usagefor the treatment of rheumatoid arthritis inpatients and outpatients. The numbers refer to the percentage ofpatients receiving a particular drug. Published data on prescribing patterns for rheumatoid arthritis are extremely limited. Information concerning NSAID drug utilisation is available but little of it is linked to morbidity (i.e., to specific forms of arthritis). Ibuprofen is currently the most widely prescribed NSAID in Britain, 7 the Netherlands,14 and in the USA,5 excluding aspirin. Naproxen is the most widely prescribed NSAID in the Scandinavian countries and in Australia. '5 In a more specific audit in a rheumatology clinic,16
where 77% of the patients had RA, indomethacin, naproxen, and ibuprofen accounted for 47% of the NSAID prescriptions. In an Australian communitybased study dealing specifically with rheumatoid arthritis,8 naproxen (25%), aspirin (25%), and indomethacin (19%) together accounted for 69% of the NSAID usage. Our study showed indomethacin and naproxen to be the first and second ranking drugs prescribed for both inpatients (67% total) and outpatients (69% total), with ibuprofen having a relatively minor role and aspirin virtually not prescribed. Statistics on consumption of SAARDs and their combination with other agents are even more scarce. Data on drug utilisation on national levels for SAARDs and corticosteroids6 are of limited value because they are not linked to diagnosis. In a British study,'6 however, 32% of outpatients received gold therapy and 17% received D- 
